Maxcyte, Inc. income statement

In fiscal 2025, Maxcyte, Inc. reported revenue of $33.0m, down 14.5% on the year before, operating income of −$51.9m (a -157.1% margin) and net income of −$44.6m, or −$0.42 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Maxcyte, Inc.: income statement, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	22	26	34	44	41	39	33	31
Cost of revenue	2	3	4	5	5	7	6	6
Gross profit	19	23	30	39	37	32	27	25
Research and development	18	18	15	20	24	22	21	17
Selling and marketing	8	8	13	19	27	27	19	14
General and administrative	6	7	19	26	30	30	28	25
Operating income	−12	−11	−18	−27	−48	−51	−52	−42
Interest expense	0	0	0	—	—	—	—	—
Income before tax	—	—	—	—	−38	−41	−45	−36
Income tax	0	0	0	—	—	—	—	—
Net income	−13	−12	−19	−24	−38	−41	−45	−36
Diluted EPS	−$0.23	−$0.17	−$0.21	−$0.23	−$0.37	−$0.39	−$0.42	−$0.33
Diluted shares (average)	56m	69m	91m	102m	103m	105m	106m	107m
EBITDA	−12	−10	−17	−25	−44	−47	−48	−38

US$ millions unless shown otherwise. Fiscal quarters.

Maxcyte, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	8	9	10	9	7	7	10	7
Cost of revenue	2	2	1	2	2	2	2	2
Gross profit	6	6	9	7	5	6	8	6
Research and development	5	5	6	6	5	3	4	4
Selling and marketing	6	6	6	6	4	4	3	3
General and administrative	8	7	9	8	6	5	6	7
Operating income	−14	−13	−12	−14	−14	−11	−6	−10
Income before tax	−12	−11	−10	−12	−12	−10	−5	−9
Net income	−12	−11	−10	−12	−12	−10	−5	−9
Diluted EPS	−$0.11	−$0.10	−$0.10	−$0.12	−$0.12	−$0.09	−$0.04	−$0.08
EBITDA	−13	−12	−11	−13	−13	−10	−5	−9

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BNGO vs MXCT MXCT vs RPID MXCT vs OABI

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Maxcyte, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Maxcyte, Inc.